---
title: "Repetitive negative thinking predicts accelerated cortical amyloid accumulation in cognitively hea"
id: "medrxiv-6-repetitive-negative-thinking-is-associated-with-amyloid-accumulation-over-3"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-6-repetitive-negative-thinking-is-associated-with-amyloid-accumulation-over-3"
content_type: "clinical_feed_article"
specialty: "Neurology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.10.29.26366526v1?rss=1"
published_at: "2026-10-31T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Repetitive negative thinking predicts accelerated cortical amyloid accumulation in cognitively hea
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-6-repetitive-negative-thinking-is-associated-with-amyloid-accumulation-over-3
- **Specialty:** [Neurology](https://medichelpline.com/clinical-feed/neurology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.10.29.26366526v1?rss=1)
- **Published At:** 2026-10-31T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The IMAP/IMAP+ longitudinal cohort followed 94 cognitively healthy adults (age mean 57.41, SD 18.31; 55% female) with up to three neuroimaging visits across three years. - Investigators measured self-reported **repetitive negative thinking (RNT)** alongside anxiety and depressive symptoms using validated scales (the source did not report exact scale names or cutpoints in the abstract). - Primary neuroimaging outcomes were change over time in global cortical **amyloid** (Florbetapir-PET), cerebral glucose metabolism (FDG-PET), and structural grey matter volume (MRI); images underwent partial volume correction and analyses used AD-relevant masks. - Linear models indicated higher RNT predicted increasing global amyloid accumulation (B = 0.0120; 95% CI 0.003 to 0.021; P = 0.012), with effects persisting in sensitivity analyses restricted to participants aged ≥50 and ≥60. - Post-hoc tertile comparisons showed a significant difference in amyloid accumulation rate between the lowest and highest RNT tertiles (P = 0.008). - Voxelwise FDR-corrected analyses localized faster amyloid increases to regions vulnerable in early AD pathology, including the precuneus, posterior cingulate cortex, and medial frontal cortex. - RNT did not predict longitudinal change in FDG-measured glucose metabolism or MRI-measured atrophy (Ps > 0.05). - Neither anxiety nor depressive symptoms were associated with change in any neuroimaging outcome (Ps > 0.05). - The authors propose that **RNT** may be an early marker or mechanistic contributor to amyloid accumulation; they note RNT is modifiable and call for trials testing whether reducing RNT affects AD risk. - The report is a medRxiv preprint and has not undergone peer review; the abstract did not provide detailed methods for RNT measurement, covariates included in models, or full statistical model specifications.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=hwSifnqmaHX2lny7X.rHT.tOPldapFzHCOTGhEwxDII-1793476853.7783802-1.2.1.1-l5n.zxIO845YXTNRORFY6Kv.KD.K0KhbbIiIkBwyXDcgq.BJQE6miPxD9u7QBu.1) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.10.29.26366526v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Repetitive negative thinking is associated with amyloid accumulation over 3 years in cognitively healthy adults Natalie L Marchant, Florence Mezenge, Anjali V Raghavan, Elise Saul, Vincent De La Sayette, The IMAP Research Group, Gaël Chételat doi: https://doi.org/10.64898/2026.10.29.26366526 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Natalie L Marchant 1 University College London Faculty of Brain Sciences; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Natalie%2BL%2BMarchant%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Marchant%20NL&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ANatalie%2BL%2BMarchant%2B) * For correspondence: n.marchant@ucl.ac.uk Florence Mezenge 2 Inserm / Université de Caen Normandie; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Florence%2BMezenge%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Mezenge%20F&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AFlorence%2BMezenge%2B) Anjali V Raghavan 1 University College London Faculty of Brain Sciences; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Anjali%2BV%2BRaghavan%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Raghavan%20AV&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAnjali%2BV%2BRaghavan%2B) Elise Saul 2 Inserm / Université de Caen Normandie; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Elise%2BSaul%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Saul%20E&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AElise%2BSaul%2B) Vincent De La Sayette 3 CHU Caen Normandie; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Vincent%2BDe%2BLa%2BSayette%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=De%20La%20Sayette%20V&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AVincent%2BDe%2BLa%2BSayette%2B) 4 - Gaël Chételat 2 Inserm / Université de Caen Normandie; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Ga%C3%ABl%2BCh%C3%A9telat%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Ch%C3%A9telat%20G&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AGa%25C3%25ABl%2BCh%25C3%25A9telat%2B) * [Abstract](https://www.medrxiv.org/content/10.64898/2026.10.29.26366526v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1335539/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.10.29.26366526v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1335539/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.10.29.26366526v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1335539/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.10.29.26366526v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1335539/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.10.29.26366526v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1335539/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Importance: Identifying potentially modifiable risk factors for Alzheimer's disease (AD) is a priority. Repetitive negative thinking (RNT) is a modifiable cognitive-emotional process common to many psychological risk factors for AD, including anxiety and depression. The psychological debt hypothesis proposes that RNT may itself increase risk for AD. Objective: To determine whether RNT symptoms are associated with change in established neurobiological markers of AD risk over time. Design: Longitudinal neuroimaging study with the IMAP/IMAP+ cohort. Setting: Monocentric with community-dwelling participants. Participants: 94 cognitively healthy adults aged 21-89 years (average 57.41 SD 18.31, 55% female) with up to 3 neuroimaging scans over a 3-year period. Exposure: All participants completed validated measures of RNT, anxiety and depression symptoms. Main Outcome(s) and Measure(s): Change over time in global cortical amyloid (Florbetapir-PET), glucose metabolism (FDG-PET), and structural grey matter volume (MRI) adjusted for potential confounders. PET images were corrected for partial volume effects, and AD-relevant masks were used for all neuroimaging outcomes. Post-hoc analyses divided the predictor variable into tertiles to aid visualisation, and FDR-corrected voxel-wise analyses were performed to identify region-specific changes. Results: RNT was associated with increasing global amyloid accumulation even after controlling for psychological symptoms (B = 0.0120, 95% Confidence Interval 0.003 to 0.021, P = 0.012), and in sensitivity analyses limited to participants aged ≥50 or ≥60. Post-hoc tests showed a significant difference in rate of amyloid accumulation between the lowest and highest RNT tertiles (P=0.008). Voxelwise analyses revealed that RNT predicted significantly faster increases in regions vulnerable to early amyloid accumulation in AD (e.g. precuneus, posterior cingulate cortex, and medial frontal cortex). RNT was not associated with change in glucose metabolism or brain atrophy (Ps>0.05). Neither anxiety nor depressive symptoms were associated with change in any neuroimaging outcome (Ps>0.05). Conclusions and Relevance: Higher RNT was associated with more rapid accumulation of cortical amyloid in regions affected early in AD. These findings indicate that this transdiagnostic cognitive-emotional process may be an early marker and/or driver of AD pathology. Given that RNT is responsive to treatment, future research is needed to investigate whether modifying RNT reduces AD risk. ### Competing Interest Statement Professor Marchant has consulted for F. Hoffmann-La Roche Ltd, with payments made to her institution. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The IMAP/IMAP + study was approved by the CPP Nord-Ouest III ethics committee. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability Data related to the current study are derived from the IMAP/IMAP+ study. The datasets used and/or analyzed during the current study are available to research groups on reasonable request and pending approval by the study coordinator. ## Funder Information Declared University of Caen Normandy (Visiting Professor programme) Fondation Plan Alzheimer (Alzheimer Plan 20082012) Programme Hospitalier de Recherche Clinique, PHRCN 2011-A01493-38, PHRCN 2012 12-006-0347 Agence Nationale de la Recherche, LONGVIE 2007 Région Basse-Normandie Association France Alzheimer et maladies apparentées, AAP 2013 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.10.29.26366526v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.10.29.26366815v1 "Prevalence, Awareness and Correlates of Self-Reported Hypoglycemia Among Adults with Type 2 Diabetes in Northern Jordan: A Cross-Sectional Study")[Next ](https://www.medrxiv.org/content/10.64898/2026.10.29.26366819v1 "Rapid direct-from-urine growth detection to triage culture-negative urine: a prospective diagnostic accuracy study of a two-tube nitrate-reduction and bromothymol blue assay \(SIBURI/SIBURI+\)") Posted October 31, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.10.29.26366526v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/10/31/2026.10.29.26366526.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.10.29.26366526v1#p-5) [ Data/Code](https://www.medrxiv.org/content/early/2026/10/31/2026.10.29.26366526.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Repetitive negative thinking is associated with amyloid accumulation over 3 years in cognitively healthy adults Natalie L Marchant, Florence Mezenge, Anjali V Raghavan, Elise Saul, Vincent De La Sayette, The IMAP Research Group, Gaël Chételat medRxiv 2026.10.29.26366526; doi: https://doi.org/10.64898/2026.10.29.26366526 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.10.29.26366526v1%26text%3DRepetitive%2520negative%2520thinking%2520is%2520associated%2520with%2520amyloid%2520accumulation%2520over%25203%2520years%2520in%2520cognitively%2520healthy%2520adults "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.10.29.26366526v1%26t%3DRepetitive%2520negative%2520thinking%2520is%2520associated%2520with%2520amyloid%2520accumulation%2520over%25203%2520years%2520in%2520cognitively%2520healthy%2520adults "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.10.29.26366526v1%26title%3DRepetitive%2520negative%2520thinking%2520is%2520associated%2520with%2520amyloid%2520accumulation%2520over%25203%2520years%2520in%2520cognitively%2520healthy%2520adults%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.10.29.26366526v1%26title%3DRepetitive%2520negative%2520thinking%2520is%2520associated%2520with%2520amyloid%2520accumulation%2520over%25203%2520years%2520in%2520cognitively%2520healthy%2520adults "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.10.29.26366526) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.10.29.26366526v1&count=horizontal&via=&text=Repetitive%20negative%20thinking%20is%20associated%20with%20amyloid%20accumulation%20over%203%20years%20in%20cognitively%20healthy%20adults&counturl=www.medrxiv.org/content/10.64898/2026.10.29.26366526v1 "Tweet This") Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (637) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (916) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (348) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (4974) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (493) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (426) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (674) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1682) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (16206) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (36) * [Gastroenterology](https://www.medrxiv.org/collection/gastroenterology) (1238) * [Genetic and Genomic Medicine](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) (7249) * [Geriatric Medicine](https://www.medrxiv.org/collection/geriatric-medicine) (751) * [Health Economics](https://www.medrxiv.org/collection/health-economics) (1092) * [Health Informatics](https://www.medrxiv.org/collection/health-informatics) (5262) * [Health Policy](https://www.medrxiv.org/collection/health-policy) (1463) * [Health Systems and Quality Improvement](https://www.medrxiv.org/collection/health-systems-and-quality-improvement) (1825) * [Hematology](https://www.medrxiv.org/collection/hematology) (599) * [HIV/AIDS](https://www.medrxiv.org/collection/hiv-aids) (1375) * [Infectious Diseases (except HIV/AIDS)](https://www.medrxiv.org/collection/infectious_diseases) (16464) * [Intensive Care and Critical Care Medicine](https://www.medrxiv.org/collection/intensive-care-and-critical-care-medicine) (1199) * [Medical Education](https://www.medrxiv.org/collection/medical-education) (696) * [Medical Ethics](https://www.medrxiv.org/collection/medical-ethics) (156) * [Nephrology](https://www.medrxiv.org/collection/nephrology) (747) * [Neurology](https://www.medrxiv.org/collection/neurology) (7552) * [Nursing](https://www.medrxiv.org/collection/nursing) (377) * [Nutrition](https://www.medrxiv.org/collection/nutrition) (1120) * [Obstetrics and Gynecology](https://www.medrxiv.org/collection/obstetrics-and-gynecology) (1293) * [Occupational and Environmental Health](https://www.medrxiv.org/collection/occupational-and-environmental-health) (1038) * [Oncology](https://www.medrxiv.org/collection/oncology) (3730) * [Ophthalmology](https://www.medrxiv.org/collection/ophthalmology) (1087) * [Orthopedics](https://www.medrxiv.org/collection/orthopedics) (405) * [Otolaryngology](https://www.medrxiv.org/collection/otolaryngology) (463) * [Pain Medicine](https://www.medrxiv.org/collection/pain-medicine) (499) * [Palliative Medicine](https://www.medrxiv.org/collection/palliative-medicine) (143) * [Pathology](https://www.medrxiv.org/collection/pathology) (720) * [Pediatrics](https://www.medrxiv.org/collection/pediatrics) (1852) * [Pharmacology and Therapeutics](https://www.medrxiv.org/collection/pharmacology-and-therapeutics) (752) * [Primary Care Research](https://www.medrxiv.org/collection/primary-care-research) (784) * [Psychiatry and Clinical Psychology](https://www.medrxiv.org/collection/psychiatry-and-clinical-psychology) (6099) * [Public and Global Health](https://www.medrxiv.org/collection/public-and-global-health) (9957) * [Radiology and Imaging](https://www.medrxiv.org/collection/radiology-and-imaging) (2515) * [Rehabilitation Medicine and Physical Therapy](https://www.medrxiv.org/collection/rehabilitation-medicine-and-physical-therapy) (1506) * [Respiratory Medicine](https://www.medrxiv.org/collection/respiratory-medicine) (1264) * [Rheumatology](https://www.medrxiv.org/collection/rheumatology) (657) * [Sexual and Reproductive Health](https://www.medrxiv.org/collection/sexual-and-reproductive-health) (799) * [Sports Medicine](https://www.medrxiv.org/collection/sports-medicine) (595) * [Surgery](https://www.medrxiv.org/collection/surgery) (799) * [Toxicology](https://www.medrxiv.org/collection/toxicology) (109) * [Transplantation](https://www.medrxiv.org/collection/transplantation) (317) * [Urology](https://www.medrxiv.org/
## Related Clinical Research

- [Autism and Menopause: Study Links Autism to More Severe Menopausal Symptoms](https://medichelpline.com/clinical-feed/medical-news-today-0-autism-is-linked-to-more-severe-menopause-symptoms-why.md)
- [ADHD medications lisdexamfetamine and atomoxetine show promise for perimenopausal brain fog](https://medichelpline.com/clinical-feed/medical-news-today-1-2-adhd-medications-show-early-promise-for-perimenopause-focus.md)
- [Exercise Timing and Cognition in Older Adults with Type 2 Diabetes and MCI: MRI RCT Protocol](https://medichelpline.com/clinical-feed/plos-one-21-effects-and-mechanisms-of-exercise-timing-on-cognitive-function-in-older-type-2.md)
- [Living with Cognitively Unimpaired Alzheimer's Disease: Insights into Preclinical Experiences](https://medichelpline.com/clinical-feed/stat-news-3-opinion-what-it-s-like-to-live-with-cognitively-unimpaired-alzheimer-s-disease.md)
- [Fewer Than 5% of U.S. Veterans Reach Optimal Cardiovascular Health Using Life’s Essential 8](https://medichelpline.com/clinical-feed/aha-news-0-fewer-than-5-of-us-military-veterans-may-achieve-optimal-heart-health.md)

## Navigation
- [← Back to Neurology Feed](https://medichelpline.com/clinical-feed/neurology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.